Journals / Retina-Vitreus / 2013 / Cilt: 21 - Sayı: 2

Current molecular and genetic advances in the retinopathy of prematurity

Prematüre retinopatisinde güncel moleküler ve genetik gelişmeler

Pages
145–153
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Understanding of the molecular mechanism in retinopathy of prematurity is extremely impor- tant in the development of new agents for the diagnosis and treatment of disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Despite significant medical and technological advances, retinopathy of prematurity is one of the major causes of visual loss in childhood in developed countries.
📊
Key Findings & Data:Retinopathy of prematurity follows the different patterns of clinical courses at preterm infants with similar clinical features.
💡
Conclusion & Impact:Understanding of the molecular mechanism in retinopathy of prematurity is extremely impor- tant in the development of new agents for the diagnosis and treatment of disease.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Despite significant medical and technological advances, retinopathy of prematurity is one of the major causes of visual loss in childhood in developed countries. Retinopathy of prematurity follows the different patterns of clinical courses at preterm infants with similar clinical features. This suggests genetic factors play role in the etiopathogenesis of the diseases such as environmental factors. Genetic researches on retinopathy of prematurity are usually carried out in animal models of oxygen induced retinopathy, and the use of these models provides a better understanding of the disease. In this article, we aimed to review the molecular factors, genetic mutations and polymorphisms that are thought to play a role in the development of retinopathy of prematurity. Understanding of the molecular mechanism in retinopathy of prematurity is extremely impor- tant in the development of new agents for the diagnosis and treatment of disease.

Özet

Prematüre retinopatisi, tıbbi ve teknolojik gelişmelere rağmen gelişmiş ülkelerde çocukluk çağı görme kayıplarının başlıca nedenlerinden biridir. Benzer klinik özelliklere sahip preterm bebeklerde pretematüre retinopatisinin farklı şekillerde sey- retmesi, hastalığın etiyopatogenezisinde çevresel faktörlerin dışında genetik faktörlerin olabileceğini düşündürmektedir. Prematüre retinopatisi ile ilgili genetik araştırmalar genelde oksijenle indüklenmiş retinopatili hayvan modellerinde yapıl- makta ve bu modellerin kullanılması hastalığın daha iyi anlaşılmasını sağlamaktadır. Bu derlemede, prematüre retinopa- tisi gelişiminde rol oynadığı düşünülen moleküler faktörler, genetik mutasyon ve polimorfizmlerlerin gözden geçirilmesini amaçladık. Prematüre retinopatisinin moleküler mekanizmasının anlaşılabilmesi, hastalığın tanı ve tedavisi için yeni ajan- ların geliştirilmesinde çok önemlidir.

🔖

Cite This Article

TEKE, Ü. A., ÇEKİÇ, O. (2013). Current molecular and genetic advances in the retinopathy of prematurity. Retina-Vitreus, Cilt: 21 - Sayı: 2, 145–153. https://ajindex.com/articles/305049

References (14)

  1. Terry TL. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. I. Prelimi- nary report. Am J Ophthalmol 1942;25:203-4
  2. Palmer EA, Flynn JT, Hardy RJ, et al. Incidence and early course of retinopathy of prematurity. Ophthalmology 1991;98:1628-40
  3. Early Treatment for Retinopathy of Prematurity Cooperative Group: Results of the early treatment for retinopathy of prema- turity randomized trial: revised indications for the treatment of retinopathy of prematurity. Arch Ophthalmol 2003;121:1684-96
  4. Csak K, Szabo V, Szabo A, et al. Pathogenesis and genetic basis for retinopathy of prematurity. Front Biosci 2006;11:908-20
  5. Dorta P, Kychenthal A, Treatment of type 1 retinopathy of prema- turity with intravitreal bevacizumab. Retina. 2010;30:24-31. 6. van Wijngaarden P, Brereton HM, Coster DJ, et al. Hereditary influences in oxygen-induced retinopathy in the rat. Doc Ophthal- mol 2010;120:87-97
  6. Askie LM, Henderson-Smart DJ, Irwig L, et al. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med 2003;349:959-67
  7. Penn JS, Henry MM, Tolman BL. Exposure to alternating hypoxia and hyperoxia casues severe proliferative retinopathy in the new- born rat. Pediatr Res 1994;36:724-31
  8. Bizzaro MJ, Hussain N, Jonsson B, et al. Genetic susceptibility to retinopathy of prematurity. Pediatrics 2006;118:1858-63
  9. Chen J, Smith LE: Retinopathy of prematurity. Angiogenesis 2007;10:133-40
  10. Chan-Ling T, Gock B, Stone J: The effect of oxygen on vasofor- mative cell division. Evidence that ‘physiological hypoxia’ is the stimulus for normal retinal vasculogenesis. Invest Ophthalmol Vis Sci 1995;36:1201-14
  11. Young TL, Anthony DC, Pierce E, et al. Histopathology and vascu- lar endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J AAPOS 1997;1:105-10. 13. van Wijngaarden P, Brereton HM, Gibbins IL, et al. Kinetics of strain- dependent differential gene expression in oxygen-induced retinopathy in the rat. Exp Eye Res 2007;85:508-17
  12. Cooke RW, Drury JA, Mountford R, et al. Genetic polymorphisms and retinopathy of prematurity. Invest Ophthalmol Vis Sci 2004;45:1712-15
  13. Vannay A, Dunai G, Banyasz I, et al. Association of genetic poly- morphisms of vascular endothelial growth factor and risk for pro- liferative retinopathy of prematurity. Pediatr Res 2005;57:396-8
  14. Kwinta P, Bik-Multanowski M, Mitkowska Z, et al. The clinical role of